BioInformant

Your Global Leader in Stem Cell Market Research

Home » exosomes

Taking EV characterization to the next level with ONI’s Nanoimager

By Leave a Comment

Extracellular vesicles (EVs) are known for their role in facilitating wide range of intercellular communication such as regulation of the immune response and stem cells differentiation.

What is an extra-cellular vesicle?

EVs are membrane-enclosed particles ranging in size from 30nm to 300nm and their characteristic depend on the cell type releasing them. Often they will carry cargo of active molecules like RNA, DNA, proteins, metabolites and lipids. Moreover, EVs can be found in most biological fluids with the ability to cross biological barriers, and in the case of pathological conditions, the composition of the cargo will be distinctive to the disease. Altogether, these features have led to intense research into the potential role of EVs for diagnostics, biomarkers and as vehicles for drug delivery. [Read more…]

Exosomes: Company Spotlights from “A” to “Z”

By

Exosomes are small vesicles ranging from 30-100nm in size that are found in nearly all eukaryotic fluids and facilitate a range of important cellular functions. They transfer DNA, RNA, and proteins to other cells, thereby altering the function of the targeted cells.

In recent years, exosomes have gained attention as a strategy for accessing the therapeutic effects of cells without the risks and difficulties of administering the cells to patients.

With at least 13,703 scientific articles published about exosomes and 169 clinical trials underway, these small vesicles have intriguing potential to be used within a range of therapeutic applications. [Read more…]

First Dosing in Plexoval Exosome Wound Healing Human Study

By

Highlights

  • First human dosing of Plexaris™ has occurred in Exopharm’s PLEXOVAL Study
  • PLEXOVAL is a world-first study using a cell free, platelet-derived exosome product manufactured using Exopharm’s proprietary LEAP Technology for wound healing
  • Other pre-clinical development progress will be reported over coming months

MELBOURNE, Australia – Jan. 29, 2020 11:00 UTC — Regenerative medicine company Exopharm Limited (ASX:EX1) announces first dosing has occurred in the PLEXOVAL Phase I study using exosomes isolated from human platelets for wound healing, Exopharm’s first human clinical trial. Further participants are expected to soon follow in this study that involves up to 20 participants. [Read more…]

Another Exosome Company Has Sprouted Up: Regen Suppliers (ReBellaXO)

By

With exosome companies rapidly populating in recent years, some of the companies have been working closely with the U.S. FDA to get a specific IND for each clinical condition. Other exosome companies have not and have been supplying their exosome products to consumers without regulatory oversight, despite the FDA being very clear that exosomes are now under their purview.  

On January 16, 2020,  yet another exosome company entered the public eye. The latest supplier of exosome products is Regen Suppliers, based in Scottsdale, Arizona. [Read more…]

Aegle Therapeutics Raises $4M to Fund First Trial in the U.S. Using Exosomes from Allogeneic MSCs

By

Aegle Therapeutics raises $4 million to fund a groundbreaking stem cell exosome clinical trial to treat the orphan disease, Dystrophic Epidermolysis Bullosa.

BOSTON and MIAMI, Jan. 7, 2020 — Aegle Therapeutics Corp., a first in class biotechnology company isolating extracellular vesicles, including exosomes (“EVs”), secreted by mesenchymal stem cells as therapy, announced the closing of a $4M financing. Aegle’s platform technology is initially being developed to treat dystrophic epidermolysis bullosa (“DEB”), a rare pediatric skin blistering disorder.  [Read more…]

BioInformant's World-Class Clients